Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 0.76 |
| ▸ | ITK | Q08881 | 3/20 | 0.76 |
| ▸ | LCK | P06239 | 2/20 | 0.76 |
| ▸ | TEC | P42680 | 3/20 | 0.76 |
| ▸ | BMX | P51813 | 3/20 | 0.76 |
| ▸ | TXK | P42681 | 2/20 | 0.76 |
| ▸ | LYN | P07948 | 2/20 | 0.76 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.76 |
| ▸ | FLT3 | P36888 | 2/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.76 |
| ▸ | LATS1 | O95835 | 1/20 | 0.76 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.76 |
| ▸ | ABL1 | P00519 | 1/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.76 |
| ▸ | FYN | P06241 | 1/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
| ▸ | CSF1R | P07333 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3362994 | 1.00 | BTK (1.00) | BTKEGFRITKLCKTEC | |
| SCHEMBL3366857 | 0.95 | BTK (0.91) | BTKEGFRITKLCKFLT3 | |
| SCHEMBL25735923 | 0.94 | BTK (0.89) | BTKEGFRITKLCKTEC | |
| SCHEMBL17951540 | 0.94 | BTK (1.00) | BTKEGFRITKLCKTEC | |
| SCHEMBL19649380 | 0.94 | BTK (1.00) | BTKEGFRITKLCKTEC | |
| SCHEMBL30615739 | 0.94 | BTK (1.00) | BTKEGFRITKLCKTEC | |
| SCHEMBL19638204 | 0.94 | BTK (1.00) | BTKEGFRITKLCKTEC | |
| SCHEMBL17951543 | 0.94 | BTK (1.00) | BTKEGFRITKLCKTEC | |
| SCHEMBL22625449 | 0.93 | BTK (0.87) | BTKEGFRITKLCKTEC | |
| SCHEMBL22625457 | 0.93 | BTK (0.87) | BTKEGFRITKLCKTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241918-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | Hefei Youyuan Pharmaceutical Co., Ltd. (CN) | 2025-07-31 | — | — | US | claimed |
| EP-4509125-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | Hefei Youyuan Pharmaceutical Co., Ltd. (CN) | 2025-02-19 | — | — | EP | claimed |
| CN-116898854-A | Novel application of pyrazolopyrimidine compound | 安徽中科拓苒药物科学研究有限公司 | 2023-10-20 | — | — | CN | claimed |
| WO-2023197914-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | 安徽中科拓苒药物科学研究有限公司 | 2023-10-19 | — | — | WO | claimed |
| US-20250241918-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | Hefei Youyuan Pharmaceutical Co., Ltd. (CN) | 2025-07-31 | — | — | US | disclosed |
| EP-4509125-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | Hefei Youyuan Pharmaceutical Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| CN-116898854-A | Novel application of pyrazolopyrimidine compound | 安徽中科拓苒药物科学研究有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3248979-B1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INST PHYSICAL SCI CAS (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-23 | — | — | US | disclosed |
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2018-02-01 | — | — | US | disclosed |
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2018-02-01 | — | — | US | disclosed |
| EP-3248979-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | Hefei Institutes of Physical Sicence, Chinese Academy of Sciences (CN) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016115869-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | 中国科学院合肥物质科学研究院 | 2016-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | FLT3, FLT1, FGFR1 | BTK 32/4885EGFR 160/4885ITK 408/4885 |
| US-20250241918-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | NLRP3, NLRP1, CASP1 | BTK 2347/4885EGFR 4797/4885ITK 2611/4885 |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | FLT3, FLT1, FGFR1 | BTK 35/4885EGFR 221/4885ITK 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.